International Patient-Physician Summit on Waldenstrom’s macroglobulinemia

Program Agenda

 

Co-Chairs:

Lia Palomba M.D., Memorial Sloan Kettering Cancer Center, New York NY, USA

Richard Furman, M.D., Weill Cornell Medical Center, New York NY, USA

Jorge J. Castillo, M.D., Dana Farber Cancer Institute, Boston MA, USA

Steven P. Treon MD, PhD, Dana Farber Cancer Institute, Boston MA, USA

 

Saturday, October 13, 2018

6:30-8:00am       Registration and Continental Breakfast

8:00-8:30am       Chairs Welcome and Program Overview of the 5th International

Patient and Physician Summit on WM

 

 

Session I              Genomics in the Diagnosis and Management of WM

Chairs: Roger Owen (UK) and Jorge Castillo (USA)

 

8:30-9:15am       Overview of MYD88 and CXCR4 mutations in WM

How can MYD88 and CXCR4 mutations be sequenced?

How important is getting MYD88 mutation status for the diagnosis of WM?

What is the role of MYD88 and CXCR4 mutations in the management of WM?

How should CXCR4 mutations be used in making treatment decisions in WM patients?

 

9:15-9:30am       Session Question and Answer Period

 

 

Session II             Predisposition to WM

Chairs: Mary McMaster (USA) and Ola Landgren (USA)

 

9:30-10:15am     Overview of known predispositions to WM

Which IgM MGUS and smoldering WM patients are at increased risk for progressing to active WM?

Does detection of mutated MYD88 in IGM MGUS patients help predict progression to WM?

What genomic changes accompany transition of IgM MGUS to WM?

How common is familial WM, and what genomics are responsible for familial disease?

Is Agent Orange exposure associated with WM?

 

10:15-10:30am   Session Question and Answer Period

 

10:30am             Morning Refreshments

 

Session III            Disease Presentation in WM

Monique Minnema (Netherlands) and Giampaolo Merlini (Italy)

 

11:00-11:45am   Overview of disease presentation in WM

What causes peripheral neuropathy in WM, and how should it be evaluated and treated?

What is Bing Neel Syndrome and how should it be evaluated?

What is Amyloidosis and when should you suspect it in WM patients?

When should plasmapheresis be used in WM patients?

 

11:45-12:00pm  Session Question and Answer Period

 

12:00-1:00pm     LUNCH

 

Session IV           Genomic Landscape of WM

Zachary Hunter (USA) and Marzia Varretoni (Italy)

 

1:00-1:45pm       Overview of key genomic findings in WM

How do MYD88 mutations impact WM cell growth and survival?

Are MYD88 mutations by themselves sufficient to cause WM?

How do CXCR4 mutations impact WM cell growth and survival?

How important are TP53 mutations in WM?

What are the treatment implications for mutations found in WM?

What genomic findings accompany disease transformation in WM?

 

1:45-2:00pm       Session Question and Answer Period

 

2:00-2:30pm       Afternoon Refreshments

                               

Session V             Clinical Trials Updates in WM: Rituximab-based therapy

Eva Kimby (Sweden) and Matthias Rummel (Germany)

 

2:30-3:30pm       Overview of rituximab alone and in combination in WM

Update of rituximab clinical trials in WM:

Bendamustine and Rituximab as first line therapy in WM

Randomized clinical trial of BCR vs. FCR as frontline therapy in WM patients

Rituximab Maintenance or Observation in WM

Activity of Rituximab in patients with MAG positive peripheral neuropathy

 

3:30-4:00pm       Session Question and Answer Period

 

4:00pm                 Day Adjournment

 

 

Sunday, October 14, 2018

 

7:30-8:30am       Registration and Continental Breakfast

 

Session VI           Clinical Trial Updates in WM: Proteasome- Inhibitors

                                Stathis Kastritis (Greece) and MJ Kersten (Netherlands)      

 

8:30-9:15am       Overview of Proteasome Inhibitor Activity in WM

Update of proteasome-inhibitor clinical trials in WM:

Long term follow-up of Bortezomib, Dexamethasone and Rituximab as frontline therapy in WM

Long term follow-up of Carfilzomib, Dexamethasone and Rituximab as frontline therapy in WM

Prospective Study of Ixazomib, Dexamethasone, Rituximab as frontline therapy in WM

Proteasome-inhibitors in previously treated WM

 

9:15-9:30am       Session Question and Answer Period

 

9:30am                 Morning Refreshments

 

Session VII          Clinical Trials Updates in WM: Ibrutinib

Steve Treon (USA) and Meletios Dimopoulos (Greece)

 

10:00-11:00am   Overview of Ibrutinib Therapy in WM

Update of ibrutinib clinical trials in WM:

Ibrutinib monotherapy in treatment-naïve WM patients

Long term follow-up of ibrutinib monotherapy in previously-treated WM patients:

Update of pivotal trial

Ibrutinib monotherapy in rituximab-refractory WM patients

Randomized clinical trial of ibrutinib/rituximab versus rituximab in symptomatic WM patients

What are the mechanisms of resistance to ibrutinib in WM?

 

11:00-11:30am   Session Question and Answer Period

 

11:30-12:30pm  LUNCH

 

Session VIII         Clinical Trials Updates in WM: Novel Agents in WM

                                Judith Trotman (Australia) and Jorge Castillo (USA)

 

12:30-1:30pm     Overview of Novel Agents in Development for WM

Update of Novel Agent Clinical Trials in WM:

Phase II Study of the BTK-inhibitor Acalabrutinib in previously-treated WM patients

Phase II Study of the BTK-inhibitor Zanubrutinib in symptomatic WM patients

Phase II Study of the BCL2-inhibitor Venetoclax in previously treated WM patients

Phase I/II Study of the CXCR4-inhibitor Ulocuplomab plus ibrutinib in symptomatic WM

Phase II Study of the CD38-antibody Daratumumab in previously treated WM patients

 

1:30-2:00pm       Session Question and Answer Period

 

Session IX            Associated and Secondary Malignancy Risks in WM Patients

Alessandra Tedeschi (Italy) and Stathis Kastritis (Greece)

 

2:30-3:00pm       Overview of other malignancies in WM

Are WM patients at higher risk for treatment unrelated cancers?

How important are treatment related secondary malignancies in WM?

What additional cancer screening should be adopted for WM patients?

 

3:00-3:15pm       Session Question and Answer Period

 

3:15pm                 Afternoon Refreshments

 

Session X             Case Presentations in WM

                                MJ Kersten (The Netherlands) and Steve Treon (USA), Moderators

 

3:30pm                 Case Presentations (4)

 

4:30pm                 Summit Adjournment                   

 

enfrdeitptrues

Sign Up for Email Updates

Summit Info

Program

Registration

Sponsors

Summit Chair
Christopher Patterson 
IPPS WM-5
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: 617.632.6285 
Fax: 617.632.4862 
Go to top
JSN Boot template designed by JoomlaShine.com